$4.78
+6.0%Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
LXEO • NASDAQ
| Lexeo Therapeutics, Inc. Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-100M | -98.3M | -66.4M | -59.3M | -50.6M | -5.2M | |
379K | 2M | 1.8M | 1.1M | 13K | 0.0 | |
12.1M | 12.5M | 3M | 1.8M | 386K | 0.0 | |
-1.6M | -23K | 530K | 0.0 | 0.0 | 1.9M | |
-9.5M | 2.7M | 1.5M | 1.8M | 6M | 150.2K | |
-98.6M | -81.2M | -59.5M | -54.6M | -44.2M | -3.1M | |
INVESTING ACTIVITIES | ||||||
-397K | -481K | -115K | -672K | -188K | (0.0) | |
-195.4M | -93.6M | (0.0) | (0.0) | (0.0) | (0.0) | |
105.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
17K | 0.0 | -50K | -229K | 0.0 | 0.0 | |
-90.3M | -94.1M | -165K | -901K | -188K | (0.0) | |
FINANCING ACTIVITIES | ||||||
217.3M | 88.7M | 100.3M | 0.0 | 0.0 | 0.0 | |
-533K | -410K | 3.6M | -163K | 0.0 | 2.6M | |
(0.0) | -17K | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 491K | -35K | 332K | -203K | -223.6K | |
216.8M | 88.8M | 103.8M | 189K | 150.9M | 32.4M | |
CASH FLOW SUMMARY | ||||||
28M | -86.5M | 44.1M | -55.3M | 106.5M | 29.2M | |
38.3M | 124.7M | 80.6M | 135.9M | 29.4M | 127.9K | |
66.2M | 38.3M | 124.7M | 80.6M | 135.9M | 29.4M | |
-99M | -81.6M | -59.7M | -55.5M | -44.4M | -3.1M |
LXEO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 27, 2026 | January 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
S-3 S-3 N/A | November 05, 2025 | November 05, 2025 |
Continue your LXEO research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.